Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Expects TripleTOF 5600 to Drive AB Sciex Revenue Growth for 2010

Premium

This story originally ran on July 22.

Danaher officials this week said the firm expects its AB Sciex division to see mid-single-digit revenue growth in 2010 based in part on sales of the company's new TripleTOF 5600 mass spectrometer.

AB Sciex introduced the instrument at the American Society for Mass Spectrometry conference in May and will begin shipments later this year (PM 5/28/2010).

In an conference call to discuss Danaher's H1 earnings, CEO Lawrence Culp said that the TripleTOF 5600 rollout is "an important launch for us."

He added that customer evaluations are currently underway, "and the feedback continues to be net positive."

Danaher's medical technologies business, which includes AB Sciex, recorded sales of $1.9 billion for H1 2010 – up 24 percent from $1.45 billion in H1 2009. The business posted an operating profit of $152 million, up 2 percent from $149 million in the year-ago period.

Culp cited costs related to the January acquisition of the AB Sciex joint venture from Life Technologies' Applied Biosystems unit and MDS.for a 240 basis point year-over-year decline in operating profit margins in the medical technologies division.

"[The integration of AB Sciex] is a fairly complicated decoupling from two parents. You've got IT systems that are being transitioned; you've got other one-time expenses like leases that are being broken to stitch this business together," he said.

In its earnings report the company noted that it "expects acquisition-related charges, primarily related to the AB Sciex and Molecular Devices acquisitions, to adversely impact the [medical technology] segment's operating profit margins through the balance of 2010, but at lower levels than experienced in the first half of 2010."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.